Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Long COVID-19 Infections and Organizing Pneumonia in a Series of Patients with Indolent Lymphoma Treated with Rituximab

David Savage, Marin Xavier, James Mason, Jacqueline Chang, Steven Escobar

Blood (2023) 142 (Supplement 1): 6133.

https://doi.org/10.1182/blood-2023-185505

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Biree Andemariam, Timothy Mant, Perla Eleftheriou, Sanne Lugthart, Lanetta Bronté-Hall, Filipa Barroso, Gershwin Blyden, James Mason, Constance M Barysauskas, Joseph Yen, Karen Tang, Rahul Ballal, Kenneth Attie

Blood (2021) 138 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2021-149536

Published: 2021

Journal Articles

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Lanetta Bronte-Hall, MD MPH, MSPH, Biree Andemariam, MD, Blyden Gershwin, MD, Sanne Lugthart, MD PhD, Timothy Mant, MB, FFPM, FRCP, Jo Howard, MBBChir, MRCP, FRCPath, Henry Fok, MBBS, PhD, Perla Eleftheriou, FRCPath, MRCP, Robert Ward Hagar, MD, James Mason, DO, Rahul Ballal, PhD, Joelle Lufkin, MPH, Eleanor Lisbon, MD MPH

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-140540

Published: 2020

Journal Articles

Drug Sensitivity Across Acute Myeloid Leukemia Subtypes Using an in Vitro Assay

Levanto Schachter, DO, MSc, Irene M. Hutchins, MD, Jill Waalen, MD MPH, Carol Burian, CCRP, Darren Finlay, PhD, Kristiina Vuori, MD PhD, Giovanni Paternostro, MD PhD, Marin F. Xavier, MD, Carrie L. Costantini, MD, William E. Miller, MD, Jeffrey Andrey, MD, James Mason, MD

Blood (2016) 128 (22): 5208.

https://doi.org/10.1182/blood.V128.22.5208.5208

Published: 2016

Journal Articles

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Blood (2013) 122 (21): 768.

https://doi.org/10.1182/blood.V122.21.768.768

Published: 2013

Journal Articles

Phase I Study of a Neutralizing Monoclonal Anti-CTLA4 Antibody (MDX-010) in Patients with Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation.

Asad Bashey, MD, PhD, Bridget Medina, Sue Corringham, RN, Mildred Pasek, Ewa Carrier, MD, Howard Streicher, MD, Israel Lowy, MD, PhD, James Mason, MD, Robert J. Soiffer, MD, Edward D. Ball, MD

Blood (2005) 106 (11): 2017.

https://doi.org/10.1182/blood.V106.11.2017.2017

Published: 2005

Journal Articles

Evidence of Donor Derived Malignancies Following Hematopoietic Stem Cell Transplantation.

Olga Sala-Torra, M.D., Michael R. Loken, Ph.D., Mary E.D. Flowers, M.D., Paula A. Ladne, M.S., James Mason, M.D, David Senitzer, Ph.D., Stephen J. Forman, M.D., Jerald Radich, M.D.

Blood (2004) 104 (11): 2247.

https://doi.org/10.1182/blood.V104.11.2247.2247

Published: 2004

NARROW

Long COVID-19 Infections and Organizing Pneumonia in a Series of Patients with Indolent Lymphoma Treated with Rituximab

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Drug Sensitivity Across Acute Myeloid Leukemia Subtypes Using an in Vitro Assay

Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America

Phase I Study of a Neutralizing Monoclonal Anti-CTLA4 Antibody (MDX-010) in Patients with Relapse of Malignancy after Allogeneic Hematopoietic Stem Cell Transplantation.

Evidence of Donor Derived Malignancies Following Hematopoietic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only